Selecting Targeted Therapy for Advanced ROS1+ NSCLC

G2032R Resistance Data Is Reshaping Second-Line Sequencing in ROS1+ NSCLC

During a virtual event, Eric K. Singhi, MD, and participants discussed how the ROS1 G2032R resistance mutation is guiding second-line therapy selection in ROS1-positive advanced non–small cell lung cancer.

With 4 Guideline-Preferred Options, CNS Activity Is Deciding Frontline ROS1+ NSCLC Therapy

During a live event, Eric K. Singhi, MD, and participants discussed how CNS activity and cumulative toxicity, not guideline listing alone, are shaping frontline treatment selection in ROS1-positive advanced NSCLC.

ROS1-Positive Lung Cancer: Key Takeaways from the Roundtable Discussions

Experts weigh newer ROS1 inhibitors like taletrectinib, highlighting long responses, fewer CNS/GI side effects, and trial challenges in rare NSCLC.

ROS1+ NSCLC: Key Takeaways From Case-Based Roundtables With Dr Santos

Edgardo Santos, MD, discusses ROS1+ NSCLC treatment advances, taletrectinib data, toxicity profiles, and emerging therapies from recent Case-Based Roundtables.

After the First TKI Fails: Sequencing Challenges in ROS1-Positive NSCLC

During a live event, Bruna Pellini, MD, and participants discussed treatment sequencing and post progression management in patients with ROS1-positive advanced non–small cell lung cancer.

The Gap Between What Oncologists Have Been Prescribing and What the ROS1 Data Now Supports

During a live event, Bruna Pellini, MD, and participants discussed frontline treatment selection for patients with ROS1-positive advanced non–small cell lung cancer, including how evolving efficacy and tolerability data are shifting practice toward newer-generation TKIs.

Taletrectinib and Brain Metastases in Non–Small Cell Lung Cancer

Explore how taletrectinib's CNS penetration may delay brain metastases and reduce the need for radiation in non–small cell lung cancer patients with ROS1.